CHA₂DS₂-VA Score Calculator

Chronic Heart Failure (1 point)1,2,3 Symptoms and signs of heart failure (irrespective of LVEF, including HFpEF, HFmrEF, and HFrEF), or the presence of asymptomatic LVEF ≤40%.
Hypertension (1 point)4,5 Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive treatment.
Age 65-74 years (1 point) Age between 65-74 years gives 1 point.
Age ≥ 75 years (2 points)6 Age 75 or older gives 2 points.
Diabetes Mellitus (1 point)7 Diabetes mellitus (type 1 or type 2), or treatment with glucose-lowering therapy.
Stroke / TIA (2 points) History of stroke, TIA, or arterial thromboembolism gives 2 points.
Vascular Disease (1 point)8,9,10 Includes coronary artery disease or peripheral vascular disease.
CHA₂DS₂-VA Score: 0

References

ESC AF Guideline 2024: For further information on the CHA₂DS₂-VA score, refer to the 2024 ESC Guidelines for the diagnosis and management of atrial fibrillation. Read the full guideline here.

1. Chung S, Kim TH, Uhm JS, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation. Am J Cardiol 2020;125:68–75. Read here.

2. Uhm JS, Kim J, Yu HT, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail 2021;8:1582–9. Read here.

3. McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation. Circ Heart Fail 2013;6:451–60. Read here.

4. McEvoy JW, Touyz RM, McCarthy CP, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024. Read here.

5. Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol 2018;72:1233–45. Read here.

6. Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrillation project. Stroke 2015;46:143–50. Read here.

7. American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care 2022;45:S17–38. Read here.

8. Steensig K, Olesen KKW, Thim T, Nielsen JC, Jensen SE, Jensen LO, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost 2018;118:2162–70. Read here.

9. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol 1998;31:1622–6. Read here.

10. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke prevention in atrial fibrillation investigators committee on echocardiography. J Am Soc Echocardiogr 1996;9:556–66. Read here.